Evaluating treatment outcome of Glioblastoma with Stupp’s regimen: an experienced in single Institute

Background The current conventional treatment approach for newly diagnosed GBM entails the complete removal of the tumor, followed by the implementation of Stupp's procedure. We assessed the results of Stupp's treatment protocol and examined certain prognostic markers associated with survival, which could offer empirical evidence in the treatment of GBM. Methods A total of 64 patients diagnosed with newly developed glioblastoma underwent treatment with irradiation and TMZ at VNCH from January 2020 to September 2022. The study provided information on the demographic and clinical features of the patients, as well as their overall survival (OS) and progression-free survival (PFS) outcomes. The analysis of survival and related variables involved the utilization of Kaplan-Meier curves, Cox regression, and the log-rank test. Results The retrospective analysis comprised 64 participants. The vast majority patients were in favorable performance status. The median OS and PFS were 24.33 and 9.39 months, respectively. Factors as female patients, GTR/STR, time to start RT within 8 weeks postoperative, no progressive disease after CCRT, no dexamethasone required and Ki67 level below 15% experienced increased OS. RegardingPFS, characteristics such as age < 40 years old, GTR/STR and no disease progression following CCRT were substantially related with improved survival. Nearly half of patients received TMZ 50mg/m2 in combination with Bevacizumab following the initial progressive illness. Conclusion Multidisciplinary collaboration, as well as advancements in diagnostic and customized treatment strategies, are critical in the treatment of GBM patients. In actual life, completing the entire Stupp's protocolsignificantly improves GBM survival.